Alain J Cohen Net Worth

The estimated Net Worth of Alain J Cohen is at least $34.5 Milion dollars as of 27 July 2010. Alain Cohen owns over 230 units of C4 Therapeutics stock worth over $28,171,230 and over the last 21 years Alain sold CCCC stock worth over $6,348,404.

Alain Cohen CCCC stock SEC Form 4 insiders trading

Alain has made over 85 trades of the C4 Therapeutics stock since 2003, according to the Form 4 filled with the SEC. Most recently Alain sold 230 units of CCCC stock worth $3,485 on 27 July 2010.

The largest trade Alain's ever made was selling 35,000 units of C4 Therapeutics stock on 8 January 2004 worth over $602,000. On average, Alain trades about 4,994 units every 23 days since 2003. As of 27 July 2010 Alain still owns at least 4,695,205 units of C4 Therapeutics stock.

You can see the complete history of Alain Cohen stock trades at the bottom of the page.

What's Alain Cohen's mailing address?

Alain's mailing address filed with the SEC is C/O C4 THERAPEUTICS, INC., 490 ARSENAL WAY #200, WATERTOWN, MA, 02472.

Insiders trading at C4 Therapeutics

Over the last 4 years, insiders at C4 Therapeutics have traded over $12,678,122 worth of C4 Therapeutics stock and bought 27,275 units worth $336,287 . The most active insiders traders include Marc A Cohen, Alain J Cohen a Elena Prokupets. On average, C4 Therapeutics executives and independent directors trade stock every 17 days with the average trade being worth of $56,874. The most recent stock trade was executed by Andrew Hirsch on 30 August 2023, trading 7,500 units of CCCC stock currently worth $45,000.

What does C4 Therapeutics do?

C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Complete history of Alain Cohen stock trades at Opiant Pharmaceuticals Inc a C4 Therapeutics

C4 Therapeutics executives and stock owners

C4 Therapeutics executives and other stock owners filed with the SEC include:

• Dr. Adam S. Crystal M.D., Ph.D.,
  Chief Medical Officer
• Andrew J. Hirsch,
  CEO, Pres & Director
• Marc A. Cohen,
  Co-Founder, Exec. Chairman & Sec.
• Dr. Kenneth C. Anderson M.D., Ph.D.,
  Co-Founder, Independent Director & Member of Scientific Advisory Board
• Kristina Zambouras,
  Director of HR
• Jolie M. Siegel J.D.,
  Chief Legal Officer
• Kendra Adams,
  Sr. VP of Communications & Investor Relations
• Dr. Stewart Fisher,
  Chief Scientific Officer
• Lauren White,
  Chief Financial Officer
• Dr. Nathanael S. Gray Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Adam Crystal,
  Chief Medical Officer
• Jolie Siegel,
  Chief Legal Officer
• Mark Mossler,
  Chief Accounting Officer
• Stephen Fawell,
  Director
• Laura Jean Wahlberg,
  VP of Finance Corp Controller
• Leonard Reyno,
  Chief Medical Officer
• Glenn Dubin,
  Director
• Marc A Cohen,
  Director
• Lauren White,
  Chief Financial Officer
• Elena Prokupets,
  Director
• Bruce Downey,
  Director
• Malcolm Salter,
  Director
• Kenneth Carl Anderson,
  Director
• William Mckee,
  Chief Financial Officer
• Stewart Fisher,
  Chief Scientific Officer
• Alain J Cohen,
  Director
• Donna Roy Grogan,
  Director
• Laura Bessen,
  Director
• Utpal Koppikar,
  Director
• Scott N Boyle,
  Chief Business Officer
• Kelly Schick,
  Chief People Officer
• Owen Hughes,
  Director
• Ronald Harold Wilfred Cooper,
  Director